AbbVie and Genmab's Epcoritamab: Why the Lymphoma Breakthrough is Still Undervalued

Related Articles

Is Talos Energy (TALO) Still Undervalued After Recent Gains

3 months ago

Why is AbbVie Investing $380 Million in US Manufacturing

4 months ago

Why Does Horizon Infrastructure Appear Undervalued

4 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

3 months ago

Category

You may also like

Stock News•5 days ago

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Genmab/AbbVie's Phase 3 EPCORE DLBCL-4 lymphoma trial met its main goal, potentially expanding the market opportunity for their therapy.

GMAB

Share

Stock News•1 week ago

After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching

Biotech M&A is resurging as Big Pharma faces patent cliffs. Recent deals like AbbVie's Apogee acquisition show buyers are paying premiums for de-risked clinical assets in oncology, obesity, and cell t...

ABBV

Share

Stock News•3 weeks ago

Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Lyell Immunopharma (LYLE) trades near cash value, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL, despite advanced pivotal trials.

CAR

Share

Stock News•2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

AbbVie beat Wall Street earnings estimates this week, fueled by strong performance in its immunology portfolio. Despite the positive results, investor sentiment remains cautious regarding the company'...

ABBV

Share